The landscape of vitiligo in Latin America: a call to action.

Vitiligo is a chronic pigmentary condition and severely impacts patient quality of life (QoL). It is an underrecognized burden for patients, healthcare systems, and society in Latin America (LA). This paper examines the journey of a vitiligo patient in LA and assesses the disease landscape. Americas Health Foundation (AHF) assembled a panel of six Argentine, Brazilian, Colombian, and Mexican vitiligo experts. On 10-12 May 2022, they met in a virtual meeting. Each panelist wrote a short paper on barriers to vitiligo diagnosis and treatment in LA before the meeting. AHF staff moderated as the panel reviewed and modified each paper over three days. The panel approved the recommendations based on research, professional opinion, and personal experience. The panel agreed that lack of disease awareness and research, social ostracization, and limited therapeutic options hinder patients in their quest for diagnosis and treatment. In addition to the medical and psychological difficulties associated with vitiligo, problems connected to the Latin American healthcare system may negatively impact diagnosis, prognosis, and treatment. Access to timely diagnosis and treatment is crucial for improving outcomes. Governments, medical societies, academics, patient organizations, industry, and the public must unite to eliminate these challenges.

Kawasaki disease mimickers.

BACKGROUND: Kawasaki disease (KD) is an acute systemic vasculitis that predominantly affects patients younger than 5 years. In the absence of an available, affordable diagnostic test, detailed clinical history and physical examination are still fundamental to make a diagnosis. METHODS: We present five representative cases with KD-like presentations: systemic onset juvenile idiopathic arthritis, mycoplasma-induced rash and mucositis, staphylococcal scalded skin syndrome, BCGosis, and the recently described multisystemic inflammatory syndrome in children (MIS-C) associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) virus. RESULTS: Rash, fever, and laboratory markers of inflammation can be present in several childhood diseases that may mimic KD. CONCLUSION: The term 'Kawasaki syndrome' instead of 'Kawasaki disease' may be more appropriate. Physicians should consider an alternative diagnosis that may mimic KD, particularly considering MIS-C during the present pandemic, as an aggressive diagnostic and therapeutic approach is needed.

Manifestaciones cutáneas en la enfermedad de orina con olor a jarabe de arce / Cutaneous alterations in maple syrup urine disease

Introducción. La enfermedad de orina con olor a jarabe de arce (EOJA), fue descrita por primera vez en 1954 por Menkes; se caracteriza por cuadro neurológico progresivo, orina con olor a caramelo y muerte inexplicable. La herencia es autosómica recesiva y la mayor incidencia se observa en población Menonita. El defecto metabólico consiste en deficiencia de descarboxilación oxidativa de los Ó-cetoácidos de cadena ramificada, derivados de los aminoácidos esenciales leucina, isoleucina y valina, que tiene como consecuencia incremento de Ó-cetoácidos en líquidos y células corporales. Casos clínicos. Reportamos tres pacientes con EOJA, de las variedades clásica e intermedia, quienes presentaron manifestaciones cutáneas llamativas en algún momento de su evolución. Conclusiones. La EOJA no produce manifestaciones cutáneas "per se", y se considera que estas son secundarias a déficit carenciales por el tratamiento

Porfiria eritropoyética congénita (enfermedades de Günter): informe de un caso / Congenital erythropoietic porphyria (Gunter's disease): report of 1 case

Se informa el caso de porfiria eritropoyética congénita en una niña; las alteraciones se presentaron en piel, dientes y orina; presentó además como problema asociado sordera. En los exámenes realizados hubo aumento de coproporfirinas y uroporfirinas en orina así como la presencia de porfirinas en haces